Digital Therapeutics Market

Digital Health Market: Focus on Digital Therapeutics, Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic disorders, Neurological disorders Respiratory disorders, Sleep disorders, Substance use disorders and Other disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    565

  • View Count
    24380

Example Insights

This image represents context of digital therapeutics market. Growing Interests in digital therapeutics, Benefits offered by digital therapeutics solutions, Industry Landscape and upcoming trends The image represents views of key stakeholders involved in the digital therapeutics market. It highlights key takeaways from interviews with key opinion leaders developing digital health solutions This infographic image represents lists of digital therapeutic solutions distribution by type of solutions The image highlights a case study to understand digital therapeutics market landscape, specifically for women's digital health solutions This infographic highlights distribution of digital therapeutics market landscape by status of development of digital therapeutics, target patient population and indications targeted by digital therapeutics
The matrix provides a view on competitive positioning of various digital therapeutic solutions based on product features / attributes (status of development, type of solution, type of therapy, purpose of solution and cost etc.) vs supplier strength The infographic highlights status of clinical trial in which digital therapeutics are being evaluated. More than 1.6 million patients have been recruited / enrolled across 500+ clinical trials registered for this novel 
class of therapies The image provides a view on level of investment that has gone into companies developing digital therapeutics This image highlights various partnerships and collaborations forged by digital therapeutic companies over the last decade This slide represents key marketing strategies adopted by digital therapeutic developers while introducing / launching their digital health solutions into the market
The infographic highlights pricing strategy framework that can be used to decide cost of digital health solutions The image highlights digital therapeutics market size for 2022-2035 period. The digital therapeutics market segmentation has been done across type of solutions, type of therapy and distribution channel adopted by digital therapeutic developers This image represents example highlights for digital therapeutics market. Digital therapeutics market by distribution by type of player, distribution by type geography, distribution by representative's designation    

Report Description

The current opportunity for curative digital solutions is prominent, representing nearly 70%-80% of the total market share of the digital therapeutics

-- Founder and CEO, a UK based small-sized company

Digital Therapeutics Market Overview

The global digital therapeutics market is anticipated to grow at a compound annual growth rate (CAGR) of 20% during the period 2022 – 2035 and is expected to be worth around USD 20 billion by 2035. Digital Therapeutics, popularly known as DTx, represent a digital health solution which delivers medical interventions directly to the patients in order to treat, manage and prevent a disease. Such solutions usually employ evidence based and clinically validated software or technologies, in order to capture real-time / real world patient data and provide improved curative response. Considering the ongoing digitization efforts and transformation of the healthcare sector, digital therapeutics have garnered significant attention from industry stakeholders and investors alike. Further, government organizations have actively undertaken initiatives, such as enactment of legislation, publishing laws and establishment of regulations, in the digital therapeutics industry. For instance, the USFDA sanctioned the Breakthrough Device Designation Program for granting approvals to digital therapeutics. It is worth mentioning that, till September 2022, around 730 digital health products (including digital therapeutics, wellness apps and digital biomarkers) had been approved by the USFDA. A similar trend was observed in other countries, such as the UK, Germany, Denmark and South Korea, where regulatory authorities have published regulations pertaining to digital therapeutics and digital health solutions. The current activity in this market and the growing demand for such solutions will drive the market growth during the forecast period.

Key Market Insights

The Digital Health Market: Focus on Digital Therapeutics (3rd Edition), 2023-2035: Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current landscape, market size and future opportunity, offering an informed opinion on the likely adoption of digital therapeutic solutions in the healthcare industry, over forecast period. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. The report answers following key questions related to this domain.

Key Advantages and Growing Demand for Digital Therapeutics

Owing to their multiple benefits, including ease of access, shorter development timelines, versatile delivery platforms, decreased cost of treatment, personalized treatment options, enhanced medication adherence, promotion of healthy lifestyle and remote access to healthcare providers for patients and vice versa, digital therapeutics have emerged as a promising alternative to conventional medication. The benefits offered by these solutions and the growing demand for remote and digital solutions across the world, post the pandemic, will drive market growth in the long term.

Global Digital Therapeutics Market Landscape

The digital therapeutics market landscape features an extensive list of more than 150 large, mid-sized, small and very small players. It is worth highlighting that over 400 digital therapeutic solutions are presently available in the market / being developed by several industry stakeholders for various target indications. It is also worth noting that majority (more than 100) of the approved / under development digital therapeutic solutions target mental health problems. Within the mental health area, indications like stress, anxiety and depression are mainly targeted by the companies. This is followed by solutions targeting neurological and metabolic disorders.

Key Drivers Behind the Digital Therapeutics Market Growth

The COVID-19 pandemic, coupled to the subsequent enforcement of mandatory social distancing measures, has created an enormous demand for remote patient engagement. Further, the evolving regulatory and clinical settings around the world have created an ample opportunity for industry stakeholders. In addition, regulatory authorities and government bodies have provided considerable support for digital therapeutics over the past few years. Moreover, the growing interest of investors in this market can be validated by the significant rise in funding activity in the recent past. Additionally, various big pharma players have undertaken several key initiatives, including strengthening their product portfolio, entering into strategic deals and making significant financial investments. Considering the active involvement of well-established industry players, the new entrants, as well as big pharma players and government organizations, the development pipeline of digital therapeutics is likely to grow further, over the forecast period. Furthermore, rising incidence of chronic diseases and associated healthcare costs will drive the adoption of digital disease management as more data pours in proving the efficacy of such devices. As per the National Center for Chronic Disease Prevention and Health Promotion, chronic diseases like diabetes, cardiovascular disease and stroke, Alzheimer’s, cancer, obesity and arthritis are some of the leading indications that account for a huge proportion of healthcare expenditure in the US. 

Overall Digital Therapeutics Market Size

Driven by the rising interest in digital and remote health solutions, the future opportunities and growth associated with the digital therapeutics, the global market is anticipated to grow at compound annual growth rate (CAGR) of 20% during the period 2022 – 2035 and is expected to be worth around USD 20 billion by 2035. Specifically, in terms of type of product, this global market is anticipated to be driven by standalone software applications based digital therapeutics, which target metabolic disorders. Diabetes management through digital therapeutics has garnered a lot of attention, with at least six prescription digital therapeutics approved in the US. All these six products received 510(k) clearance and require a prescription from a clinician.

North America Holds the Largest Digital Therapeutics Market Share

In addition to this, presently, close to 90% of the market is captured by players based in North America and Europe. A bill, Access to Prescription Digital Therapeutics Act of 2023, was introduced in the Senate in March 2023; when passed, it will expand the coverage of prescription digital therapeutics and, hence, their adoption in the US. However, in the long term, the digital therapeutics market in Asia is anticipated to grow at a relatively faster pace during the forecast period. Rising incidence of chronic diseases like diabetes, increasing use of smartphones and access to improved internet services will be the key market drivers.

Leading Digital Therapeutics Companies

Examples of key players engaged in digital therapeutics market (which have also been profiled in this report) include (in alphabetical order) Ampersand Health, Akili Interactives, Better Therapeutics, Brain+, Click Therapeutics, CogniFit, GAIA, Healios, JOGO Health, Jolly Good, KORE Digital Health Therapeutics, Livongo Health, Lucid, MedRhythms, Pear Therapeutics, Redicare Control, Susmed, The Learning Corp, Voluntis and WellDoc.

Scope of the Report

Global Digital Therapeutics Market: Market Segmentations.

Key Report Attributes Details

Forecast Period

2023 – 2035

Type of Solution

Standalone Software Application, Software Application + Device, Software Application + AI Support, Software Application + Personal Coach, Software Application + Device + AI Support, Software Application + Device + Personal Coach and Others

Type of Therapy

Curative Solutions, and Preventive Solutions

Purpose of Solution

Medication Replacement and Medication Augmentation

Type of Business Model

B2B and B2C

Therapeutic Area

Cardiovascular disorders, Chronic Pain, Mental Health Problems, Metabolic disorders, Neurological disorders, Respiratory disorders, Sleep disorders, Substance use disorders and Other disorders

Key Geographical Area

North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World

The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in digital therapeutics industry. Amongst other elements, the report includes:

  • An executive summary of the key insights captured during our research, offering a high-level view on the current state of the digital therapeutics market and its likely evolution in the short to mid and long term.
  • A brief introduction to important concepts related to digital therapeutics, featuring information on various types of digital therapeutics and its primary applications in the healthcare domain. Further, this chapter features details related to the recent advancements that have been reported in this market space.
  • An overview of the current market landscape of digital therapeutics solutions, including information on status of development, type of solution (combination offering of software application and device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target indication(s), therapeutic area and target population. In addition, it presents details related to the companies engaged in developing digital therapeutics solutions, highlighting their year of establishment, company size, type of business model (B2B and B2C) and location of their headquarters.
  • An in depth analysis, highlighting the contemporary market trends, using three schematic representation, including a 4-D bubble analysis for comparing the leading players engaged in the development of digital therapeutics solutions (based on the parameters, such as product portfolio strength, number of target indication(s) and company size), an insightful tree map representation of the digital therapeutics solutions (distributed on the basis of therapeutic area and company size), and a world map representation (highlighting the regional distribution of developer companies).
  • A detailed product competitiveness analysis of digital therapeutics solutions that are available / under development for the most popular therapeutic areas, taking into consideration strength of the product portfolio (based on the number of digital therapeutic solutions being developed for that therapeutic area) and key product specific parameters, such as status of development, type of solution, type of therapy, prescription requirement and purpose of solution.
  • Elaborate profiles of prominent large, mid-sized and small players that are either engaged in the development or have developed digital therapeutics solutions. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolio, recent developments and an informed future outlook.
  • An analysis of completed, ongoing and planned clinical studies of digital therapeutics, various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for top ten recent initiated trials for popular therapeutic areas).
  • An analysis of funding and investments received by companies engaged in the digital therapeutics’ market, during the period 2016-2022, including grants, debt financing, seed funding, venture series, initial public offering, secondary offerings, private placements and other equity.
  • An in-depth analysis of partnerships that have been inked between various stakeholders during the period 2016-2022, covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements,  product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, product development agreements, research and development agreements, and commercialization agreements. 
  • A detailed analysis of various business models and go-to-market strategies adopted by firms engaged in developing digital therapeutics solutions, highlighting details on various channels adopted by the stakeholders in order to raise awareness and offer access to their proprietary products.
  • A Bowman’s clock pricing strategy framework analyzes the competitive position of various companies engaged in this domain, taking into consideration the prices and different features of their products. In addition, it presents an equation devised to calculate the likely price of digital therapeutics based upon their characteristics.
  • A detailed market forecast analysis in order to estimate the existing market size and the future opportunity for digital therapeutics developers over the next decade. Based on multiple parameters, likely adoption trends and expected price variations of these products, we have provided an informed estimate of the evolution of the market during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the digital therapeutics market across type of solution (combination offering of software application and device or AI or personal coach, and standalone software applications), purpose of solution (medication replacement and medication augmentation), type of therapy (curative and preventive), business models (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • A detailed assessment of the overall market landscape of women’s digital health solution developers, along with information on their year of establishment, company size, location of headquarters, type of solution(s) offered (applications / software, devices and services), along with their current status of development, product ratings, application area, usage during different stages of pregnancy, purpose of solution and type of end-users. 
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutics industry.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders (in alphabetical order of company name): 

  • Radhika Kamalia (Chief of Staffs to CEO and Strategy Lead, Ampersand Health)
  • Adam Kaufman (Ex-Chief Executive Officer, Canary Health)
  • Cindy Zhang (Marketing Director, Dnurse Technology)
  • Healther Ritchie (Chief Strategy Officer, Embr Labs)
  • Hooman Lee (Founder and Chief Executive Officer, Exosystems)
  • Vijay Ravindran (Chief Executive Officer, Floreo) 
  • Stan Sugarman (Chief Commercial Officer, GAIA)
  • Guilhem Dupnot (Chairman and Chief Executive Officer, Healios)
  • Siva Nadarajah (Co-Founder and President, JOGO Health)
  • Tim Rudolphi (Chief Executive Officer, metaMe Health)
  • Soren Kleberg (Chief Executive Officer, SelfBack)
  • Eran Ofir (Ex-Chief Executive Officer, Somatix)
  • Edouard Gasser (Chief Executive Officer, Tilak Healthcare)
  • Torin Block (Chief Executive Officer, Turnaround Health)
  • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
  • Amelie Janson (Ex-Communication Manager, Voluntis)
  • Palakh R Sarogi (Ex-Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Ex-Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Ex-Marketing and Public Relations, Wellthy Therapeutics)
  • Anonymous (Founder and Chief Executive Officer, UK based Small Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are digital therapeutics?

Answers: Digital therapeutics, also known as DTx, represent a type of digital health solution which delivers medical interventions directly to the patients, using an evidence based, clinically validated software or a combination of software, in order to treat, manage and prevent a disease or disorder

Question 2: What are the most popular therapeutic areas being targeted by digital therapeutics?

Answers: Majority (close to 30%) of the marketed / under development digital therapeutic solutions target mental health disorders. This can be attributed to the steep rise observed in THE incident of mental health disorders, such as anxiety, depression and stress, during and post the pandemic, across the globe. It is also worth highlighting that neurological and metabolic disorders are other popular therapeutic areas targeted by the digital therapeutic solutions.

Question 3: What is the likely size of the digital therapeutics market? 

Answers: The global digital therapeutics market is anticipated to grow at a compound annual growth rate of 20% over the next 13 years and is expected to be worth around USD 20 billion by 2035.

Question 4: Which region is leading in the digital therapeutics market?

Answers: Currently, North America and Europe collectively hold 80% of the market share. In the long run, the digital therapeutics market in Asia is likely to grow at a relatively faster pace.

Question 5: What are the key factors influencing the price of digital therapeutic solutions?

Answers: Digital therapeutic solutions are priced based on factors, such as complexity, target patient population, cost of development and delivery, competition, perceived value and  regulatory settings. Complex solutions utilizing technologies, such as artificial intelligence or machine learning, may be more expensive. 

Question 6: What is the trend of capital investments in the digital therapeutics market?

Answers: Owing to the lucrative market opportunity associated with digital therapeutics, several investors have collectively invested over USD 20 billion. 

Question 7: Which types of partnerships are usually signed in the digital therapeutics industry?

Answers: Commercialization agreements, pilot product offerings and product / technology integration agreements are the most common type of partnership models adopted by stakeholders engaged in the digital therapeutics’ domain.

Question 8: Which marketing strategies are commonly adopted for digital therapeutics?

Answers: Most of the players involved in the digital therapeutics’ domain have adopted the in-bound marketing strategies in order to enhance their company and product visibility. It is worth highlighting that majority of the players have used Facebook, You-Tube and LinkedIn as the most preferred social media platforms for in-bound marketing.

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions

3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification

3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics

3.5.2. Typical Development and Commercialization Path for Digital Therapeutics 
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing 

3.6 Concluding Remarks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy    
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area 
4.2.7. Analysis by Target Population 

4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution

4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters

4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders 
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders    
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive 
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook     

6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook 

6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook     

6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook     

6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook 

6.10. Voluntis
6.10.1. Company Overview
6.10.2.    Product Portfolio
6.10.3.    Recent Developments and Future Outlook

6.11. WellDoc
6.11.1.    Company Overview
6.11.2.    Product Portfolio
6.11.3.    Recent Developments and Future Outlook

6.12. Wellthy Therapeutics
6.12.1.    Company Overview
6.12.2.    Product Portfolio
6.12.3.    Recent Developments and Future Outlook     

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Digital Therapeutics: Clinical Trial Analysis    
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10.    Analysis by Type of Sponsor
7.3.11.    Analysis by Focus Area
7.3.12.    Analysis by Geography
7.3.13.    Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14.    Analysis of Patients Enrolled by Geography

7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models

8.3. Digital therapeutics: List of Funding and Investments
8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10.    Most Active Investors: Analysis by Number of Instances

8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS 
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations 
9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership 
9.3.2.2. Analysis by Type of Partnership and Company Size

9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner 
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3. Analysis by Type of Partner and Company Size

9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy

9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2. Analysis by Type of Partner and Therapeutic Area

9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2.    Marketing on Social Media Platforms
10.2.3.    Marketing on Online / Print Media Platforms
10.2.4.    Undertaking Various Promotional Activities through Official Websites
10.2.5.    Adoption of Different Business Models 
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model

10.2.6.    Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2.    Eight Positions on Bowman Strategic Clock

11.3. Roots Analysis Framework
11.3.1. Methodology
11.3.2.    Theoretical Framework and Price Evaluation Hypothesis
11.3.3.    Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035

12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software         Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035

12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035

12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035

12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035

12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035

12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035

12.10. Concluding Remarks

13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area

13.4. Women’s Digital Health: Developer's Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors 
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview 
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Radhika Kamalia, Chief of Staffs to CEO and Strategy Lead 

15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Adam Kaufman, Ex-Chief Executive Officer

15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Cindy Zhang, Marketing Director 
    
15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Healther Ritchie, Chief Strategy Officer      

15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Hooman Lee, Founder and Chief Executive Officer      

15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Vijay Ravindran, Chief Executive Officer 

15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Stan Sugarman, Chief Commercial Officer

15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Guilhem Dupnot , Founder and Chief Executive Officer

15.10. JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript: Siva Nadarajah, Co-Founder and President

15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2. Interview Transcript: Tim Rudolphi, Chief Executive Officer

15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript: Soren Kleberg, Chief Executive Officer

15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript: Eran Ofir, Ex-Chief Executive Officer 

15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript: Edouard Gasser, Chief Executive Officer

15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript: Torin Block, Chief Executive Officer

15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer

15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript: Amelie Janson, Ex-Communication Manager

15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript: Palakh R Sarogi, Ex-Vice President Marketing, Arani Sarkra Ex-Senior Manager Consumer Marketing, and Yolande D’Mello, Ex-Marketing and Public Relations

15.19. Undisclosed
15.19.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer

16. CONCLUDING REMARKS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Digital Health: Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in the Healthcare Sector
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Type of Solution
Figure 4.3 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.4 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Target Indication
Figure 4.7 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Digital Therapeutics: Distribution by Target Population
Figure 4.9 Digital Therapeutic Solutions: Distribution by Prescription Requirements
Figure 4.10 Digital Therapeutic Solutions: Distribution by Duration of Course
Figure 4.11 Digital Therapeutic Solutions: Distribution by Cost of Solutions (USD)
Figure 4.12 Digital Therapeutic Developers: Distribution by Year of Establishment
Figure 4.13 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.14 Digital Therapeutics Developers: Distribution by Business Model
Figure 4.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutic Solutions
Figure 4.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Figure 4.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Figure 4.19 Digital Therapeutics: Distribution of Regional Activity (World Map Representation)
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018-2023)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018-2023)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018-2023)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018-2023)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018-2023)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018-2023)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 Big Health: Digital Therapeutics Products and Clinical Trial Outcomes
Figure 6.3 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.4 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Study Age
Figure 7.10 Clinical Trial Analysis: Distribution by Gender of Patients
Figure 7.11 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Figure 7.12 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.13 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 7.15 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Figure 7.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.17 Clinical End-Points Analysis
Figure 7.18 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.19 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Figure 8.3 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 8.5 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Figure 8.7 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Figure 8.9 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Figure 8.10 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Figure 8.11 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Figure 8.12 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Figure 8.13 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution of Instances by Geography
Figure 8.15 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 8.16 Most Active Players: Distribution by Number of Instances
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 8.18 Most Active Investors: Distribution by Number of Instances
Figure 8.19 Funding and Investment Summary, Pre-2019-2022 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016 - 2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016 - 2022
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016 - 2022
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Figure 9.11 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Adoption of Different Business Model
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, 2022-2035 (USD Million)
Figure 12.2 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications 2022-2035 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Types of Solutions, 2022-2035 (USD Million)
Figure 12.10 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035 (USD Million)
Figure 12.13 Digital Therapeutics Market: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 12.14 Digital Therapeutics Market for Curative Therapies, 2022-2035 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapies, 2022-2035 (USD Million)
Figure 12.16 Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Figure 12.17 Digital Therapeutics Market for B2C Model, 2022-2035 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model, 2022-2035 (USD Million)
Figure 12.19 Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2022-2035 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2022-2035 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2022-2035 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders 2022-2035 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2022-2035 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2022-2035 (USD Million)
Figure 12.29 Digital Therapeutics Market: Distribution by Geography, 2022-2035 (USD Million)
Figure 12.30 Digital Therapeutics Market in North America, 2022-2035 (USD Million)
Figure 12.31 Digital Therapeutics Market in Europe, 2022-2035 (USD Million)
Figure 12.32 Digital Therapeutics Market in Asia, 2022-2035 (USD Million)
Figure 12.33 Digital Therapeutics Market in MENA, 2022-2035 (USD Million
Figure 12.34 Digital Therapeutics Market in Latin America, 2022-2035 (USD Million
Figure 12.35 Digital Therapeutics Market in Rest of the World, 2022-2035 (USD Million)
Figure 13.1 Women’s Digital Health: Distribution by Type of Solution
Figure 13.2 Women’s Digital Health: Distribution by Status of Development
Figure 13.3 Women’s Digital Health: Distribution by Product Ratings
Figure 13.4 Women’s Digital Health: Distribution by Application Area
Figure 13.5 Women’s Digital Health: Distribution of Products used during Stages of Pregnancy
Figure 13.6 Women’s Digital Health: Distribution by Purpose of Solution
Figure 13.7 Women’s Digital Health: Distribution by Type of End-Users
Figure 13.8 Women’s Digital Health: Distribution by Type of Solution and Application Area
Figure 13.9 Women’s Digital Health Developers: Distribution by Year of Establishment
Figure 13.10 Women’s Digital Health Developers: Distribution by Company Size
Figure 13.11 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Figure 13.12 Women’s Digital Health Developers: Distribution by Company Size and Region
Figure 13.13 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Figure 13.14 Leading Players: Distribution by Number of Solutions
Figure 13.15 Regional Landscape: Distribution by Type of Solution
Figure 14.1 Digital Therapeutics: Overview of SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.6 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 MindMaze: Company Snapshot
Table 6.15 MindMaze: Digital Therapeutic Solutions Portfolio
Table 6.16 MindMaze: Recent Developments and Future Outlook
Table 6.17 Omada Health: Company Snapshot
Table 6.18 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.19 Omada Health: Recent Developments and Future Outlook
Table 6.20 Pear Therapeutics: Company Snapshot
Table 6.21 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.22 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.23 Vida Health: Company Snapshot
Table 6.24 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.25 Vida Health: Recent Developments and Future Outlook
Table 6.26 Voluntis: Company Snapshot
Table 6.27 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.28 Voluntis: Recent Developments and Future Outlook
Table 6.29 WellDoc: Company Snapshot
Table 6.30 WellDoc: Digital Therapeutic Solutions Portfolio
Table 6.31 WellDoc: Recent Developments and Future Outlook
Table 6.32 Wellthy Therapeutics: Company Snapshot
Table 6.33 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.34 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount Invested and Investor(s), 2016 - 2022
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise)
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 11.1 Product Price Evaluation Matrix: Based on Status of Development
Table 11.2 Product Price Evaluation Matrix: Based on Type of Solution
Table 11.3 Product Price Evaluation Matrix: Based on Purpose of Solution
Table 11.4 Product Price Evaluation Matrix: Based on Type of Therapy
Table 11.5 Product Price Evaluation Matrix: Based on Therapeutic Area
Table 11.6 Product Price Evaluation Matrix: Based on Prescription Requirement
Table 11.7 Product Price Evaluation Matrix: Based on Duration of Course
Table 11.8 Product Price Evaluation Matrix: Based on Distribution Channel
Table 15.1 Company Snapshot: Ampersand Health
Table 15.2 Company Snapshot: Canary Health
Table 15.3 Company Snapshot: Dnurse Technology
Table 15.4 Company Snapshot: Embr Labs
Table 15.5 Company Snapshot: Exosystems
Table 15.6 Company Snapshot: Floreo
Table 15.7 Company Snapshot: GAIA
Table 15.8 Company Snapshot: Healios
Table 15.9 Company Snapshot: JOGGO Health
Table 15.10 Company Snapshot: metaMe Health
Table 15.11 Company Snapshot: SelfBack
Table 15.12 Company Snapshot: Somatix
Table 15.13 Company Snapshot: Tilak Healthcare
Table 15.14 Company Snapshot: Turnaround Health
Table 15.15 Company Snapshot: Vida Health
Table 15.16 Company Snapshot: Voluntis
Table 15.17 Company Snapshot: Wellthy Therapeutics
Table 17.1 Digital Therapeutics: Distribution by Status of Development
Table 17.2 Digital Therapeutics: Distribution by Type of Solution
Table 17.3 Digital Therapeutics: Distribution by Type of Therapy
Table 17.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 17.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 17.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 17.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 17.8 Digital Therapeutics: Distribution by Target Population
Table 17.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 17.10 Digital Therapeutics: Distribution by Duration of Course
Table 17.11 Digital Therapeutics: Distribution by Cost of Solution (USD)
Table 17.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Digital Therapeutics Developers: Distribution by Company Size
Table 17.14 Digital Therapeutics Developers: Distribution by Business Model
Table 17.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 17.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutics Solutions
Table 17.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Table 17.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Table 17.19 Digital Therapeutics: Distribution by Regional Activity
Table 17.20 Cardiovascular Disorders: Shift in Trends (2018 - 2023)
Table 17.21 Mental Health Problems: Shift in Trends (2018 - 2023)
Table 17.22 Metabolic Disorders: Shift in Trends (2018 - 2023)
Table 17.23 Neurological Disorders: Shift in Trends (2018 - 2023)
Table 17.24 Substance Use Disorders: Shift in Trends (2018 - 2023)
Table 17.25 Other Therapeutic Areas: Shift in Trends (2018 - 2023)
Table 17.26 Clinical Trial Analysis: Scope and Methodology
Table 17.27 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Table 17.28 Clinical Trial Analysis: Distribution by Trial Status
Table 17.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.31 Clinical Trial Analysis: Distribution by Type of Study
Table 17.32 Clinical Trial Analysis: Distribution by Study Design
Table 17.33 Clinical Trial Analysis: Distribution by Study Age
Table 17.34 Clinical Trial Analysis: Distribution by Gender of Patients
Table 17.35 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Table 17.36 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 17.37 Clinical Trial Analysis: Distribution by Focus Area
Table 17.38 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.39 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Table 17.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 17.41 Clinical End-Points Analysis
Table 17.42 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Table 17.43 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Table 17.44 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Table 17.45 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Table 17.47 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Table 17.50 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Table 17.52 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Table 17.53 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Table 17.54 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Table 17.55 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Table 17.56 Funding and Investment Analysis: Distribution of Instances by Geography
Table 17.57 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 17.58 Most Active Players: Distribution by Number of Instances
Table 17.59 Most Active Players: Distribution by Amount Raised (USD Million)
Table 17.60 Most Active Investors: Distribution by Number of Instances
Table 17.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016-2022
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016-2022
Table 17.64 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 17.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016-2022
Table 17.67 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 17.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 17.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 17.70 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Table 17.71 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Table 17.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 17.74 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Partnerships
Table 17.76 Partnerships and Collaborations: Regional Distribution
Table 17.77 Partnerships and Collaborations: Country-Wise Distribution
Table 17.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 17.80 Go-to-Market Strategy: Online / Print Media Platforms
Table 17.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 17.82 Go-to-Market Strategy: Adoption of Different Business Model
Table 17.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 17.84 Overall Digital Therapeutics Market, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.85 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 17.86 Digital Therapeutics Market for Standalone Software Applications, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.87 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.88 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.89 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.90 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.91 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.92 Digital Therapeutics Market for Other Type of Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.93 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035 (USD Million)
Table 17.94 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2022 and 2035 (USD Million)
Table 17.97 Digital Therapeutics Market for Curative Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.98 Digital Therapeutics Market for Preventive Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.99 Global Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Table 17.100 Digital Therapeutics Market for B2C Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.101 Digital Therapeutics Market for B2B Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 17.103 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.104 Digital Therapeutics Market for Chronic Pain, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.105 Digital Therapeutics Market for Mental Health Problems, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.106 Digital Therapeutics Market for Metabolic Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.107 Digital Therapeutics Market for Neurological Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.108 Digital Therapeutics Market for Respiratory Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.109 Digital Therapeutics Market for Sleep Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.110 Digital Therapeutics Market for Substance Use Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.111 Digital Therapeutics Market for Other Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.112 Global Digital Therapeutics Market: Distribution by Geography, 2022 and 2035
Table 17.113 Digital Therapeutics Market in North America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.114 Digital Therapeutics Market in Europe, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.115 Digital Therapeutics Market in Asia, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.116 Digital Therapeutics Market in MENA, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.117 Digital Therapeutics Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.118 Digital Therapeutics Market in Rest of the World, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.119 Women’s Digital Health: Distribution by Type of Solution
Table 17.120 Women’s Digital Health: Distribution by Status of Development
Table 17.121 Women’s Digital Health: Distribution by Product Ratings
Table 17.122 Women’s Digital Health: Distribution by Application Area
Table 17.123 Women’s Digital Health: Distribution by Products Usage with respect to Pregnancy
Table 17.124 Women’s Digital Health: Distribution by Purpose of Solution
Table 17.125 Women’s Digital Health: Distribution by Type of End-Users
Table 17.126 Women’s Digital Health: Distribution by Type of Solution and Application Area
Table 17.127 Women’s Digital Health Developers: Distribution by Year of Establishment
Table 17.128 Women’s Digital Health Developers: Distribution by Company Size
Table 17.129 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.130 Women’s Digital Health Developers: Distribution by Company Size and Region
Table 17.131 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.132 Leading Players: Distribution by Number of Solutions
Table 17.133 Regional Landscape: Distribution by Type of Solution

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 2048 Ventures
  2. 23andMe
  3. 2breathe Technologies
  4. 2Morrow
  5. 3L Capital
  6. 3M Ventures
  7. 3VC
  8. 4FO Ventures
  9. 4point0
  10. 500 Startups
  11. 5AM Ventures
  12. 7wire Ventures
  13. 8VC
  14. 98point6
  15. 9Unicorns
  16. A Better Weigh
  17. A-Round Capital
  18. a thousand colibris  
  19. A195 Capital
  20. Aavia
  21. Ababax Health
  22. Abbott
  23. AbbVie
  24. AbleTo
  25. Accel
  26. Acceleration Partners
  27. Accelmed Partners 
  28. Accolade
  29. Act Venture Capital
  30. Aculys Pharma 
  31. Advance Venture Partners
  32. Advanced Circulatory Systems
  33. Advanced Maternity Innovations
  34. Advantage Capital
  35. Advantage Consumer Healthcare
  36. Aequus Pharmaceuticals
  37. Aetna
  38. Aflac Corporate Ventures
  39. AH Warren Trust
  40. AI Fund
  41. AIA Group
  42. AIB Seed Capital Fund
  43. Aindra Systems
  44. Airbus
  45. Akili Interactive
  46. Akilia Partners
  47. Al-Ahli Hospital
  48. Albion Capital
  49. AlbionVC
  50. Alex Therapeutics
  51. Alfvén & Didriksson
  52. Alife Health
  53. Alkeon Capital Management
  54. Allara Health
  55. Allen & Company
  56. A.G.P./ Alliance Global Partners
  57. Allianz Partners
  58. Ally Bridge Group
  59. Allysian Sciences
  60. Almirall
  61. Alpha Femtech
  62. Alsace Business Angels
  63. AltaIR Capital
  64. Althea Group 
  65. Altitude Ventures
  66. Altoida
  67. Alumni Ventures
  68. Amadeus Capital Partners
  69. Amalgam
  70. Amar Seva Sangam
  71. Amara Therapeutics
  72. Amazon Smbhav Venture Fund
  73. Amazon Web Service (AWS)
  74. Amboy Street Ventures
  75. AME Cloud Ventures
  76. Amelia
  77. American Association of Diabetes Educators
  78. American Diabetes Association
  79. Intermountain Healthcare
  80. American Investment Holdings
  81. American Stroke Association
  82. Amgen Ventures
  83. Amiko
  84. aMoon
  85. Ampersand Health
  86. Amplify Capital
  87. Ananda Impact Ventures.
  88. Anastasia Kovba
  89. Anchorless Bangladesh
  90. Ancora Finance Group
  91. Andera Partners
  92. Andreessen Horowitz
  93. AngelList
  94. Anorak Ventures
  95. Anthem
  96. Anthemis Exponential Ventures
  97. Anthemis
  98. AOA Dx
  99. Aphelion Capital
  100. AppBasic
  101. Appalachian Regional Healthcare
  102. AppliedVR
  103. Apricity
  104. Apricity Health
  105. Aptar
  106. Aptar Pharma
  107. Arbor Health
  108. Arboretum Ventures
  109. Ardea Partners
  110. ArlanWasHere Investments
  111. ArrowMark Partners
  112. Artesian
  113. Arthritis New Zealand
  114. Asabys Partners
  115. Asahi Kasei Corporate Ventures Capital
  116. Ascensia Diabetes Care
  117. Ascension Brighton Center for Recovery
  118. Ascension Ventures
  119. Aspect Ventures
  120. Aspivix
  121. Asset Management Ventures
  122. Astellas Pharma
  123. Astinno
  124. AT&T
  125. Athena Feminine Technologies
  126. Atheneum 
  127. Atlantic Labs
  128. Atlantic Therapeutics
  129. AtlasV Global
  130. ATMA Journey Centers
  131. Atomico
  132. ATX Therapeutics
  133. Australasian College of Behavioural Optometrists (ACBO)
  134. Autism Impact Fund
  135. Autism Learning Partners
  136. Autonomous Open Innovation (AOI)
  137. Ava Women (Acquired by FemTec)
  138. Avaana Capital
  139. Avestria Ventures
  140. Aviva Ventures
  141. Avricore Health
  142. Awakn Life Sciences
  143. Awesome People Ventures
  144. AXA
  145. AXA Venture Partners (AVP)
  146. Axia Women’s Health
  147. B Capital Group
  148. Baby2Body
  149. Babyscripts
  150. Backstage Capital
  151. Baillie Gifford
  152. balance-app
  153. Balderton Capital
  154. Banner|Aetna
  155. Baseline Ventures
  156. Bayer
  157. Bayer G4A
  158. BBG Ventures
  159. BlueCross BlueShield Venture Partners
  160. Beats Medical
  161. Beaumont Hospital
  162. BeCareLink
  163. Beehive Holdings
  164. BEENEXT 
  165. BehaVR
  166. Bellabeat
  167. Beneufit
  168. Bertelsmann India Investments
  169. Bessemer Venture Partners
  170. Bethnal Green Ventures
  171. Better Therapeutics
  172. Bettermeant Health
  173. Beyond Next Ventures
  174. BGF
  175. Bia Med
  176. Big Health
  177. Bill Lucia
  178. Bimark
  179. Biocon
  180. BIOCORP
  181. Biofourmis
  182. Biogen
  183. Biomedix
  184. BioTrak Therapeutics
  185. Biovotion
  186. BIXINK Therapeutics
  187. BJC Healthcare
  188. Blackbird Ventures
  189. Blackstone Growth
  190. Blessing Health System
  191. bLife
  192. Bliss Digital Therapeutics
  193. Bloom Burton & Co
  194. Bloomer Tech
  195. Bloomlife
  196. Bloomth
  197. Blossom Capital
  198. Blue Cross and Blue Shield of Kansas City (Blue KC)
  199. Blue Cross Blue Shield of Arizona
  200. Blue Cross Blue Shield of Massachusetts
  201. Blue Cross Blue Shield of Michigan
  202. Blue Cross Blue Shield Venture Partners
  203. Blue Mesa Health
  204. Blue Note Therapeutics
  205. Blue Ox Healthcare Partners
  206. Blue Shield of California
  207. Blue Water Life Science Fund
  208. Blueprint Health
  209. BlueRun Ventures
  210. BOC Healthcare
  211. Boehringer Ingelheim
  212. Boehringer Ingelheim Venture Fund
  213. Bold Capital Partners
  214. Bold Health
  215. Bolt Ventures
  216. Bonit Capital
  217. Bonnier Ventures
  218. Bonzun
  219. Borski Fund
  220. Bose Ventures
  221. Boston Medical Center
  222. Bpifrance
  223. Brain Power
  224. Brain+
  225. BrainFx
  226. Braster
  227. Breastlink
  228. BreezoMeter
  229. Bridge Bank
  230. Bridge Builders Collaborative
  231. Bridge Health Medical
  232. BridgeHealth
  233. BrightCap Ventures
  234. Brilliantly Warm
  235. Bristol-Myers Squibb
  236. Brooklands Capital Strategies
  237. btov Partners
  238. Buoy Health
  239. Burst IQ
  240. Business Health Care Group
  241. B-wom
  242. Cabin VC
  243. Caffeinated Capital
  244. Caixa Capital Risc
  245. Calpro AS
  246. Cambridge Design Partnership
  247. Cambridge Digital Health
  248. Cambridge Femtech Society
  249. Canaan Partners
  250. Canary Health
  251. Cancer Institute Hospital of JFCR 
  252. Candlelit Therapy
  253. Canepa Advanced Healthcare Fund
  254. Canopie
  255. Canvas Ventures
  256. Capier Investments
  257. capital300
  258. Cara Care
  259. Carbomed Medical Solutions
  260. CardioRenal
  261. Care4Cute
  262. CareFirst
  263. CareLinx
  264. CareSignal
  265. CAREvolution
  266. Carlyle
  267. Carrot & Company
  268. Carrot Health (Acquired by Unite Us)
  269. Carrum Health
  270. CASA SEAT
  271. Casdin Capital
  272. Castlight Health
  273. Catasys
  274. Cayaba Care
  275. Cedars-Sinai Medical Center
  276. Celebrate the Children
  277. Centene Corporation
  278. Cerner Corporation
  279. CerpassRx
  280. CES Unveiled
  281. CG Ventures
  282. Charles River Ventures
  283. CheckUp & Choices
  284. Chiaroscuro Foundation
  285. Chibagin Capital
  286. Chiesi 
  287. Children’s Community Health Plan
  288. Children’s Hospital of Philadelphia
  289. Chorus Community Health Plans
  290. Chopra Foundation
  291. Chorus Health
  292. Chugai Pharmaceutical
  293. Cigna
  294. Cigna Ventures
  295. Cipla
  296. City Light Capital
  297. Civilization Ventures
  298. Claritas Health Ventures
  299. Clarkson University
  300. Clementine app
  301. Click Therapeutics
  302. CLSA
  303. Clue by Biowink
  304. CogniFit
  305. Cognoa
  306. Collaborative Fund
  307. Collective Health
  308. COLOPL VR Fund
  309. Community Health Network of Connecticut.
  310. Companion Medical
  311. Company K Partners
  312. Company Ventures
  313. Competitive Health
  314. Comprehensive Pain Specialists
  315. Concord Health Partners
  316. Conference Series
  317. Connors Center 
  318. Consortium Health Plans
  319. CoreHealth Technologies
  320. Cority
  321. Coroflo
  322. Correlation Ventures
  323. Cortado Ventures
  324. Costco Wholesale
  325. Council For Trade and Investment Promotion (CTIP)
  326. Cowen Private Investments
  327. COYA Partners
  328. CRCM Ventures
  329. Creandum
  330. Creas Impacto
  331. Creative Destruction Lab
  332. Crescent Ridge Partners
  333. Crimsonox Capital
  334. Crista Galli Ventures
  335. Crohn's & Colitis Foundation
  336. Crossroads Treatment Centers
  337. Curavit Clinical Research
  338. CureApp
  339. Curebase
  340. Curio Digital Therapeutics
  341. Currae Healthtech Fund
  342. Toyoshima CVC
  343. CVS Health Ventures
  344. Cyberdine
  345. dacadoo
  346. Dai-ichi Life
  347. DAK Gesundheit 
  348. Dario Health
  349. Dartmouth College
  350. Dayzz
  351. Debiopharm
  352. Deerfield Management 
  353. Delivering Scientific Innovation for Autism
  354. Deloitte
  355. Dendera Ventures
  356. United States Department of Defense 
  357. United States Department of Veteran Affairs
  358. Development Bank of Wales
  359. Dexcom
  360. Dexium Technologies
  361. DFJ Growth
  362. Danish Diabetes Association
  363. Diabnext (Acquired by Glooko)
  364. Diasend
  365. Digbi Health
  366. DG Daiwa Ventures
  367. Digital Health Acquisition 
  368. Digital Health Today
  369. Digithera
  370. DigiTx Partners
  371. Dignity Health
  372. DN Capital
  373. Dnurse Technology
  374. Doctor on Demand
  375. Doha Tech Angels
  376. Dopavision
  377. Double Peak 
  378. Downing Ventures
  379. Dragoneer Investment
  380. Draper Esprit and Touchstone Innovations
  381. DrChrono
  382. Dream Incubator
  383. Dreamit Ventures
  384. Dreem
  385. Driehaus Capital Management
  386. Droobi Health
  387. dTHx
  388. Duke University School of Medicine
  389. Duopharma Biotech Berhad
  390. e&
  391. Ease Healthcare
  392. Echo Health Ventures
  393. eClinicalHealth
  394. Eco-Fusion
  395. EDBI
  396. Eden Strategy Institute
  397. Efficient Capacity Fund
  398. Ehave
  399. EHE Health
  400. Ei.Ventures
  401. Eisai
  402. EIT Health
  403. ElaWoman
  404. Elda Health
  405. Electronics and Telecommunication Research Institute (ETRI)
  406. Elevance Health
  407. Eli Health
  408. Eli Lilly
  409. Elidah
  410. Ellerca Health
  411. EloCare
  412. Elvie
  413. Elysium Venture Capital
  414. Embr Labs
  415. Emme
  416. Emotional Intelligence Ventures
  417. Endeavor Catalyst
  418. Endeavour Vision
  419. Endodiag
  420. Endometrix
  421. ENDRA Life Sciences
  422. Enovis
  423. Enso (Acquired by Hinge Health)
  424. Enterprise Ireland
  425. Enterprise Ireland Commercialisation Fund
  426. Entreé Capital
  427. Enzia Ventures
  428. EQT Ventures
  429. eQventure
  430. Ermua City Council
  431. Eurazeo
  432. European Commission
  433. European Innovation Council
  434. European Innovation Council and SMEs Executive Agency (EISMEA)
  435. Eurostars
  436. Evernorth’s Health 
  437. Evernow
  438. EVERSANA
  439. EvidentIQ
  440. Evidity Health Capital
  441. Exandus
  442. Exosystems
  443. Expon Capital
  444. Express Script
  445. Faegre Drinker
  446. Fairhaven Health
  447. Farallon Capital Management
  448. Fearless Ventures
  449. Feel Therapeutics
  450. Felicis Ventures
  451. Femasys
  452. FemCy
  453. FEMM
  454. Femna Health
  455. Femometer
  456. FemTec Healthcare
  457. FemTech Analytics
  458. FemTech Focus
  459. FemX
  460. Fenbushi Capital
  461. Ferne
  462. Ferrer
  463. Fertility Focus
  464. FetoLife
  465. Fidelity Management and Research Company
  466. Fifty Years
  467. FinTLV Ventures
  468. Finnish Student Health System (FSHS)
  469. Fireside Ventures
  470. First Nation Group
  471. First Round Capital
  472. FirstCheck Africa
  473. FirstMark Capital
  474. Fish & Richardson
  475. Fit4D
  476. Fitterfly
  477. Fizimed
  478. Flare Capital Partners
  479. Flint Capital
  480. Flo Health
  481. Flöka
  482. Floreo
  483. Florida Hospital
  484. Flying Health
  485. FMZ Ventures
  486. Fondation pour l'Innovation Technologique (FIT)
  487. Fontys Hogeschool ICT
  488. Ford Motor Company
  489. Forerunner Ventures
  490. Foresight Group
  491. Forth Management
  492. Fortunis Capital
  493. Founder Institute
  494. Founders Fund
  495. Foundry Group
  496. F-Prime Capital
  497. Frame Fertility
  498. Franklin Templeton
  499. Fred Hutchinson Cancer Research Center
  500. Freespira
  501. Freestyle Capital
  502. Frist Center for Autism and Innovation
  503. Frontier Venture Capital
  504. Frost & Sullivan
  505. Frøya Life
  506. Fruit Street 
  507. Frumtak Ventures
  508. Fuel Ventures
  509. Future\Perfect Ventures
  510. Future Positive Capital
  511. FWD Takaful
  512. GAIA
  513. Gaido Health (Acquired by Biofourmis)
  514. Gaingels
  515. Gallagher Student Health & Special Risk
  516. Gals Bio
  517. Games for Health
  518. Garmin
  519. gBETA Medtech
  520. GC VR Tracker Fund
  521. Gedeon Richter
  522. Gelt Venture Capital
  523. General Atlantic
  524. General Catalyst
  525. General Catalyst 
  526. Genesis Ventures
  527. Gennev
  528. Genoa Telepsychiatry
  529. Georgian
  530. Giant Leap
  531. Gilde Healthcare
  532. Ginger
  533. GingerBread Capital
  534. GlaxoSmithKline
  535. Global Brain 
  536. Global Founders Capital
  537. GlobalYeast
  538. Glooko
  539. Glow Inc
  540. Golden Seeds
  541. Google
  542. Grand Central Tech
  543. Great Heights Family Medicine
  544. Green Shield Canada
  545. Greycroft
  546. GrowX Ventures
  547. Grupo Fleury
  548. GSK NEXT
  549. GSR Ventures
  550. GuideWell Mutual Holding Corporation
  551. gumi Cryptos Capital (gCC)
  552. GV
  553. H.I.G. BioHealth Partners
  554. Hackster.io
  555. Hadean Ventures
  556. Halza
  557. Hambrecht Ducera Growth Ventures
  558. Hannover Re US
  559. Happify Health
  560. Harvard Business School Association of Northern California (HBSANC)
  561. Harvard Medical School
  562. Harvard University
  563. HAX
  564. Haxus
  565. Headspace
  566. Healios
  567. Health & Her
  568. Health Allliance Plan
  569. Health Catalyst
  570. Health Catalyst Capital
  571. Health Enterprise Partners (HEP)
  572. Health in Her HUE
  573. Healthmine
  574. Health Transformation Alliance
  575. HealthCap
  576. Healthcare Innovation Fund
  577. Health Inn
  578. HealthPartners
  579. HealthXL
  580. Healthy Trucking Association of America
  581. Heartcore Capital
  582. Hedia
  583. HelloBetter
  584. Hello Heart
  585. HelloFresh
  586. HeraMED
  587. Hercules Capital
  588. Heritas Capital
  589. Heuristic Capital
  590. Hevella Capital
  591. Highmark Health
  592. Highmark Interactive
  593. High-Tech Gründerfonds
  594. Higi
  595. Hikma Ventures
  596. Hinduja Group
  597. Hinge Health
  598. HITLAB
  599. Hiventures
  600. HLM Venture Partners
  601. HMA Capital Partners
  602. Holmusk
  603. Horizon 2020
  604. European Innovation Council (EIC)
  605. Hubble Connected
  606. Human API
  607. Humana
  608. Hyde Park Angels
  609. Hygieia
  610. IBB Ventures
  611. IBH Population Health Solutions
  612. iBreve
  613. Icon Ventures
  614. Idinvest Partners
  615. Ieso Digital Health
  616. iFeel Labs
  617. IIB Sant Pau
  618. Illinois Department of Healthcare and Family Services
  619. Illumigyn
  620. Illumina Ventures
  621. ImagineMIC™
  622. Insan Mulia Abditama 
  623. Impact Ventures UK
  624. IMPUTE Inc.
  625. Incos Invest
  626. Indegene
  627. India Edison Accelerator
  628. India Innovation Initiative
  629. Industry Ventures
  630. INFOR Financial 
  631. Information Technology Academia Collaboration (ITAC)
  632. InHealth Ventures
  633. Inito
  634. inMotion VR
  635. inne
  636. Innovation Skåne
  637. InnovHealth 
  638. Inova
  639. Insight Partners
  640. Insignia Ventures Partners
  641. Sant Pau Biomedical Research Institute (IIB Sant Pau)
  642. Institute of Mental Health (IMH)
  643. Insulet
  644. InsurTech.vc
  645. Integra Community Care Network
  646. Integra Partners
  647. Intel Capital
  648. Intermountain Ventures
  649. International Capital Management
  650. International Finance Corporation (IFC)
  651. International Medical Center Apps
  652. International Technology Law Association (ITechLaw)
  653. Invest Detroit
  654. Investec Ventures
  655. ION Crossover Partners
  656. IP Group
  657. IPD Capital
  658. IPOPEMA Securities
  659. Ironwood Pharmaceuticals
  660. iSeed Ventures
  661. iSono Health
  662. Itamar Medical
  663. Iterative Capital 
  664. IT-Farm
  665. ITOCHU
  666. ITOCHU Technology Ventures
  667. IVP
  668. Iwagin Business Creation Capital
  669. Iwagin Jigyo Souzou Capital
  670. iXensor
  671. J.P. Morgan
  672. JamJar Investments
  673. Janssen Pharmaceutica NV
  674. Janssen Research & Development
  675. January Ventures
  676. JAZZ Venture Partners
  677. Jennis
  678. Jianke
  679. Jichi Medical University
  680. JJDC
  681. JOGO Health
  682. Johns Hopkins HealthCare Solutions
  683. Johnson & Johnson
  684. Johnson & Johnson Innovation
  685. Johnson Venture Partners (JVP)
  686. Joint Academy
  687. Jolly Good
  688. Joy Ventures
  689. Joyable
  690. Joyance Partners
  691. K2 HealthVentures
  692. K2 Investment Partners
  693. Kaia Health
  694. Kakao Ventures
  695. Kamet Ventures
  696. Kapor Capital
  697. Karista
  698. Karolinska Institutet
  699. Karuna Labs
  700. KEGG (Kyoto Encyclopedia of Genes and Genomes)
  701. Keio Innovation Initiative
  702. Kelvi
  703. Kenetic Capital
  704. Kentucky Science and Technology Corporation (KSTC)
  705. Kheiron Medical Technologies
  706. Khosla Ventures
  707. Khyria
  708. Kicker Ventures
  709. Kiio
  710. Kima Ventures
  711. Kindbody
  712. King River Capital
  713. King's College London
  714. Kinnevik
  715. KiOmed Pharma
  716. KLAVA Innovation
  717. Kleiner Perkins Caufield & Byers
  718. Kleiner Perkins Caufield & Byers (KPCB)
  719. Koa Health
  720. Konna xyz
  721. KORE Digital Health Therapeutics
  722. Korea Advanced Institute of Science and Technology
  723. Korea Technology Finance 
  724. Korea Investment Partners
  725. Kormeli
  726. Kortex Ventures
  727. Koshidaka Holdings
  728. KTB Network
  729. Kurbo Health
  730. Kwit
  731. Kyma Medical Technologies
  732. Kyushu University
  733. LabQ International
  734. BlackRock Private Equity Partners
  735. Lactamo
  736. LactApp
  737. Lactation Lab
  738. Ladera Venture Partners
  739. Laguna Investment
  740. LAIA
  741. Laia 
  742. Laidir Foundation
  743. Lark Health
  744. Launchpad Venture Group
  745. Lead Edge Capital
  746. League of Innovators
  747. Leap Fitness Group
  748. Leaps by Bayer
  749. Learn Behavioral
  750. Learn 
  751. Leerink Transformation Partners
  752. Leksell Social Ventures
  753. Lemonaid Health
  754. LetsGetChecked
  755. LexisNexis Risk Solutions
  756. Lief Therapeutics
  757. LifeScan
  758. Life Science Innovation Fund (LSI)
  759. Lifeforce Capital
  760. Lifeline Ventures
  761. LifeSense Group (LSG)
  762. Lifestyle & Wellness Medical Center
  763. Lightspeed Venture Partners
  764. Limbix
  765. Linchpin Healthcare
  766. LionBird Ventures
  767. Liquid 2 Ventures
  768. Liriro
  769. Lisa Health
  770. LiveBetter
  771. Livia
  772. Livongo Health
  773. LongHash Ventures
  774. Louisiana Department of Health
  775. LRVHealth
  776. LSP
  777. LUCID
  778. Lucina Analytics
  779. Luma Womb
  780. LumiraDx
  781. LUNA-endometriose 
  782. Lund University
  783. Lux Capital
  784. M Venture Partners (MVP)
  785. M Ventures
  786. M12, Microsoft's Venture Fund
  787. Mabel
  788. Mae
  789. Magellan Health
  790. Magic Horizons
  791. Magnetic Ventures
  792. Mahana Therapeutics
  793. Mahmee
  794. MAIF Avenir
  795. Maine Technology Institute
  796. Maki.vc
  797. Mana Ventures
  798. Mangrove Capital Partners
  799. Manhattan Venture Partners
  800. Manipal Education and Medical Group
  801. MannKind 
  802. Manulife
  803. MAP Health Management
  804. MAPFRE
  805. Mass General Brigham
  806. Massachusetts General Hospital
  807. Massachusetts Institute of Technology (MIT)
  808. MassChallenge
  809. MassMutual Ventures
  810. Material Impact
  811. Materna Medical
  812. Maven Clinic
  813. Maven Ventures
  814. Maverick Ventures
  815. Maveron
  816. Maya Digital Health
  817. Mayden
  818. Mayo Clinic
  819. MBS innovation DRIVE
  820. McKesson Ventures
  821. McKinsey
  822. McLean Hospital
  823. MDLIVE
  824. Medical Mutual of Ohio
  825. Medifox Dan
  826. MediPeace Vietnam
  827. I-Medita
  828. MedRhythms
  829. MedTech Entrepreneurs
  830. Medtech Women
  831. Medtronic
  832. Medvest Capital
  833. MEEZA
  834. Meliora Technology
  835. Melon Health
  836. Mementor (Acquired by ResMed)
  837. Memorial Sloan Kettering Cancer Center (MSKCC) 
  838. MemorialCare Innovation Fund (MCIF)
  839. Menopod
  840. Mercer
  841. Merchavia
  842. Merck
  843. Merck Global Health Innovation Fund
  844. M Ventures
  845. Meridian Street Capital
  846. Meritech Capital Partners
  847. Mersey Care NHS Foundation Trust
  848. Meru Health
  849. Meta
  850. metaMe
  851. MetFlux Research
  852. Metrocare Services
  853. Metrodora Ventures
  854. Metronomic 
  855. Microsoft
  856. Midlands Engine Investment Fund (MEIF)
  857. MiLA Capital
  858. MiMARK
  859. Min Doktor
  860. Mindable Health
  861. MindBeacon Group
  862. Mind Cure Health
  863. Mindmaze
  864. Mindset Health
  865. MindWise Innovations
  866. MINES & Associates
  867. Mira
  868. Mirae Assets
  869. Mitsubishi UFJ Capital
  870. I Mercury Capital
  871. Mizuho Capital
  872. MJog
  873. MobileODT
  874. Mobio Technologies
  875. Modern Fertility
  876. Molbio Diagnostics
  877. Molten Ventures
  878. Monarch Medical Technologies
  879. Monashee Investment Management
  880. Monkfish Equity
  881. Montage Ventures
  882. MooDoos Investments
  883. Moonai
  884. Moonwhale Ventures
  885. More Provident Funds
  886. Morningside
  887. Morningside Group
  888. Mountain Group Partners
  889. MoveUp
  890. MTIP
  891. Mundi Ventures
  892. Mundipharma
  893. MUTU System
  894. MyAva
  895. My mhealth
  896. Myant
  897. MyLife ID
  898. Nabta Health
  899. Nagoya City University
  900. Naluri
  901. Nantahala Capital Management
  902. National Breast Cancer Foundation
  903. National Cancer Center (NCC)
  904. National Cancer Institute
  905. National Cancer Institute (NCI)
  906. National Center of Neurology and Psychiatry (NCNP)
  907. National Education Association (NEA)
  908. National Health Service (NHS)
  909. National Healthcare Group (NHG)
  910. National Heart Centre Singapore (NHCS)
  911. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  912. National Institute of Mental Health
  913. National Institute on Aging
  914. National Institutes of Health (NIH)
  915. National Rheumatoid Arthritis Society
  916. National Science Foundation
  917. National Science Foundation (NSF)
  918. National Technical University of Athens (NTUA)
  919. Natural Cycles
  920. Navitus Health Solutions
  921. Naytal
  922. NCL Technology Ventures
  923. National Education Association (NEA)
  924. Nebrija University
  925. Nest Collaborative
  926. Neuberger Berman Funds
  927. Neuroglee Therapeutics
  928. NeuroMetrix
  929. Neurotrack
  930. New England-Israel Business Council (NEIBC)
  931. New Enterprise Associates
  932. New Leaf Venture Partners
  933. Meritain Health
  934. New Mexico Retiree Health Care Authority (NMRHCA)
  935. Newsenselab
  936. Newtopia
  937. Nex Cubed
  938. Next AI
  939. NEXT Canada
  940. NextGen Venture Partners
  941. Nexus Venture Partners
  942. NGP Capital
  943. NHL Alumni Association
  944. NightWare
  945. National Institute of Health (NIH)
  946. Nimble Ventures
  947. Nimbus Synergies
  948. Nina Capital
  949. Niramai
  950. Noaber
  951. Nokia Growth Partners
  952. Noom
  953. Nordic Brain Tech
  954. Nordic Eye Venture Capital
  955. Nori Health
  956. Northwell Holdings
  957. Norwest Venture Partners
  958. Novartis
  959. Novartis Venture Fund
  960. Novator Partners
  961. Novo Holdings
  962. Novo Nordisk
  963. NSI Ventures
  964. Nunaps
  965. NursElet
  966. Nuvo Group
  967. Oak HC/FT
  968. Oath Care
  969. Ocean Azul Partners
  970. OCON Healthcare
  971. Octopus Ventures
  972. Okhlahoma Health Care Authority
  973. Oky
  974. Olive Tree Capital
  975. Olive Tree Ventures
  976. Omada Health
  977. Omega Capital Partners
  978. Omidyar Technology Ventures
  979. Omron Corporation
  980. Oncology Care Home Health Specialists
  981. One Drop
  982. ONE WORLD Training & Investments
  983. Ontario Telemedicine
  984. Oova
  985. Openspace Ventures
  986. Operator Partners
  987. Optum Ventures
  988. Opus Growth
  989. Oratel Diagnostics
  990. OrbiMed
  991. Ordinary Folk
  992. Örebro University
  993. Orexo
  994. Orion
  995. Orreco
  996. OSF Ventures
  997. Ospedale Malcantonese (OSCAM)
  998. Otsuka America
  999. Otsuka Health Solutions
  1000. Otsuka Pharmaceutical 
  1001. Oula Health
  1002. OurCrowd
  1003. Outcomes fund
  1004. Ovia Health
  1005. Ovira
  1006. Ovulai
  1007. Ovulation Calculator
  1008. Owl Health
  1009. Owl Ventures
  1010. Oxeon
  1011. Oxford Academic Health Science Network
  1012. Oxford University
  1013. Ozential Digital Therapeutics
  1014. PaceZero Capital Partners
  1015. Pachamama
  1016. Pacific Health Ventures
  1017. Pallasite Ventures
  1018. Palo Alto Medical Foundation
  1019. Parasail Health
  1020. Parentlane
  1021. Parian Global Management
  1022. Partum Health
  1023. Pathology Asia
  1024. Payor Logic
  1025. PayPal
  1026. PBJ Capital
  1027. Pear Therapeutics
  1028. Pegasus Tech Ventures
  1029. Pepapp
  1030. Peramare
  1031. Perceptive Advisors
  1032. PeriGen
  1033. Pfizer
  1034. PFM Health Sciences
  1035. Phenomenal Women's Health
  1036. Phenomenelle Angels
  1037. Philips
  1038. Phoenix Insurance
  1039. Physera
  1040. pi Ventures
  1041. Picus Capital
  1042. Pilot House
  1043. Pixvana
  1044. Plackal Tech 
  1045. Plan International
  1046. Playwing
  1047. Plug and Play Tech Centre
  1048. Polaris Partners
  1049. Polytech Ventures
  1050. Pomelo Care
  1051. Pond Capital
  1052. Pontifax Venture Capital
  1053. Portland Seed Fund
  1054. PreemieWorld
  1055. PregnaScan
  1056. Premera Blue Cross
  1057. Presence Capital
  1058. Primary Health Care Corporation (PHCC)
  1059. Prima-Temp
  1060. Prime Therapeutics
  1061. Prime Venture Partners
  1062. Prism Healthcare
  1063. Privia Health
  1064. Privitar
  1065. Proactive for her
  1066. Prodeko Ventures
  1067. Prognos Health
  1068. Progyny
  1069. Proov
  1070. Propeller Health
  1071. Prority Health
  1072. Protocol Labs
  1073. Prototron
  1074. Providence Health & Services
  1075. Providence Ventures
  1076. Pruksa Group
  1077. PsyInnovations
  1078. pumpspotting
  1079. Punchbowl
  1080. Pura Vida Investments
  1081. Purdue University
  1082. PureTech Health
  1083. QBIC - Qatar Business Incubation Center
  1084. Qiming Venture Partners
  1085. QUAD Investment Management
  1086. Quadrille Capital
  1087. Qualcomm Life
  1088. Quiver Tree Investments
  1089. Qure Ventures
  1090. Raiing Medical
  1091. Rally Health
  1092. Raydiant Oximetry
  1093. Reaktor Ventures
  1094. Red One Medical
  1095. RedBrick Health
  1096. Redbrick
  1097. Redicare Control
  1098. Redmile Group
  1099. Redox
  1100. Reflectance Medical
  1101. Region Östergötland
  1102. Region Skåne
  1103. Renalis
  1104. Renovia
  1105. Research Society for The Study of Diabetic in India (RSSDI)
  1106. ResMed
  1107. Resolute Ventures
  1108. Restore Health
  1109. Rethink Impact
  1110. Revelation Partners
  1111. Revive Therapeutics
  1112. Revon Systems
  1113. Rhia Ventures
  1114. RHL Ventures
  1115. RhythmiaBreath
  1116. RISE (Research Institutes of Sweden)
  1117. Ro
  1118. Roblox
  1119. Roche
  1120. Roche Diabetes Care
  1121. Roche Diagnostics
  1122. RoX Health
  1123. Royal Society of Medicine 
  1124. RRE Ventures
  1125. RS Investments
  1126. Russell Siegelman
  1127. S.R. One
  1128. Saama Capital
  1129. Safar Partners
  1130. Safeguard Scientifics
  1131. Sage Capital Partners
  1132. Sagentia Innovation
  1133. Saisei Ventures
  1134. Saison Ventures
  1135. Salem Partners
  1136. SalesForce
  1137. Salumedia
  1138. Samsung
  1139. Samsung Health
  1140. Sandoz
  1141. Sano
  1142. Sanofi
  1143. Sanofi Ventures
  1144. Santora Nakama
  1145. SAP
  1146. Sapiens Ventures
  1147. Sapphire Ventures
  1148. Sarissa Capital
  1149. Sarjan Health
  1150. SBI Investment 
  1151. Scale Capital
  1152. Schoolhouse Partners
  1153. Scientific Federation
  1154. Scientific Med
  1155. SD Venture
  1156. Seashore Solutions
  1157. Sectoral Asset Management
  1158. SEED Capital 
  1159. SeedtoB Capital
  1160. SelfBack
  1161. Sennheiser
  1162. Senseonics
  1163. Seoul National University Bundang Hospital
  1164. Sequoia Capital
  1165. Sequoia India
  1166. Sera Prognostics
  1167. Seraph Venture
  1168. Serena Ventures
  1169. Seroba Life Sciences
  1170. Servier
  1171. Sevenlogics
  1172. SGInnovate
  1173. Shanda Group
  1174. Sharecare
  1175. Shareholder Value Management
  1176. She Loves Tech
  1177. Shinsei Bank
  1178. Shinsei Corporate Investment
  1179. Shionogi
  1180. Shire Pharmaceuticals
  1181. Sidekick Health
  1182. Sidgetop Health
  1183. Signant Health
  1184. Silicon Valley Bank
  1185. Silver Cloud Health
  1186. Silver Lake
  1187. Simon & Schuster
  1188. Simplyhealth
  1189. Sivan Innovation
  1190. Skånsk Innovationskraft
  1191. SMBC Venture Capital
  1192. Social Starts
  1193. Softbank 
  1194. SoftBank Vision Fund
  1195. SoftTech
  1196. Solera Health
  1197. SOMA Breath
  1198. SOMPO Digital Lab
  1199. Sompo Holdings
  1200. Sonormed
  1201. Sonova Group
  1202. Sony Innovation Fund
  1203. SOSV
  1204. Sozo Ventures
  1205. SparkLabs
  1206. Sparrow Ventures
  1207. Speak AI
  1208. Spice Capital
  1209. Spring Mountain Capital
  1210. Springboard
  1211. Springbuk
  1212. SR One
  1213. Srirakshaa Healthcare
  1214. Stanford Technology Ventures Program
  1215. Stanford University
  1216. Stanford University Mind & Body Lab
  1217. Stanford University School of Medicine
  1218. Stanley Park Ventures
  1219. Starting Line
  1220. Startmate
  1221. StartUp Health
  1222. Startupbootcamp Digital Health Berlin
  1223. StartX Fund
  1224. Stateline Angels
  1225. StayWell
  1226. SteadySense
  1227. Steelcase
  1228. SteelSky Ventures
  1229. SternAegis Ventures
  1230. Stewart Greenebaum
  1231. Stifel GMP
  1232. Storka
  1233. Storm Ventures
  1234. Stress Point Health
  1235. Stripes
  1236. Sumitomo Dainippon Pharma
  1237. Sumitomo Mitsui Trust Investment
  1238. Summer VC
  1239. Summit Partners
  1240. Summit Reinsurance Services
  1241. SureHire
  1242. Susmed
  1243. SVB Ventures
  1244. SVC
  1245. Sway Ventures
  1246. Swedish Breast Cancer Association
  1247. Sweet Capital
  1248. Sweetch
  1249. Swing Therapeutics
  1250. Swiss Healthcare Startups (SHS)
  1251. Swiss Re
  1252. Symphony Ventures
  1253. Syrona Health
  1254. Tal Capital
  1255. TALi Health
  1256. Tamtris Web Services
  1257. Target
  1258. Target Global
  1259. Tech Up For Women
  1260. Tech4Eva
  1261. Techammer
  1262. Techstars
  1263. Teijin
  1264. Teladoc Health
  1265. TELUS Ventures
  1266. Tempdrop
  1267. Tennessee Department of Intellectual and Developmental Disabilities (DIDD)
  1268. Terumo
  1269. Texas HALO Fund
  1270. The Aplastic Anemia & MDS International Foundation
  1271. The Body Literacy Collective
  1272. The Female Health Hub
  1273. The Harris Center for Mental Health and IDD
  1274. The Learning Corp
  1275. The Lily Project
  1276. The Pelvic Expert
  1277. Regents of the University of California
  1278. The Research Foundation for The State University of New York 
  1279. The Shoko Chukin Bank
  1280. The University of Texas Health Science Center at Houston (UTHealth)
  1281. The Venture Reality Fund
  1282. The Vertical Group
  1283. Thimble Point
  1284. Think Bigger Capital
  1285. Think.Health
  1286. Tia
  1287. Tiger Global Management
  1288. Tilak Healthcare
  1289. Titan Capital  
  1290. Tokyo Century
  1291. Tooly Tech
  1292. TOYOSHIMA
  1293. Trend Forward Capital
  1294. TrialSpark
  1295. Trinity Capital
  1296. Triumf Health
  1297. TruDiary
  1298. True Ventures
  1299. Trustbridge
  1300. TT Capital Partners
  1301. Turnaround Health
  1302. Tutorify
  1303. U.S. Venture Partners
  1304. Ubicom Holdings
  1305. UCB
  1306. UCI Health
  1307. Uncork Capital
  1308. Union Square Ventures
  1309. Unique Nutrition Solutions
  1310. United Healthcare
  1311. United Nations University International Institute for Global Health (UNU-IIGH)
  1312. UnityPoint Health Ventures
  1313. Universal Music Group
  1314. University Hospitals
  1315. University of Applied Sciences and Arts of Southern Switzerland (SUPSI)
  1316. University of California
  1317. University of Missouri
  1318. University of Nebraska Medical Center 
  1319. University of New York
  1320. University of Pennsylvania
  1321. University of Sydney
  1322. University of Washington
  1323. Unum
  1324. UpLift Health
  1325. Upright Technologies
  1326. Uvi Health
  1327. VA Palo Alto Health Care System 
  1328. Validic
  1329. VCapital 
  1330. Vectr Ventures
  1331. Vectura
  1332. Veera Health 
  1333. Velmio
  1334. Venrock
  1335. Venture Catalysts
  1336. Venture Kick
  1337. Venture Partners
  1338. Vicore Pharma
  1339. Victorum Capital Club
  1340. Vida Health
  1341. Vigo
  1342. Virgin Pulse
  1343. Virta Health
  1344. Virtue Health
  1345. Vitadio
  1346. Vitality Group
  1347. Vivant
  1348. Vivid Vision
  1349. VNV Global
  1350. Voluntis
  1351. VSP Vision Care
  1352. Wachanga
  1353. Wake Forest University
  1354. Wakestream Ventures
  1355. Walking Ventures
  1356. Wallgreens
  1357. Wanxiang America Corporation
  1358. Watkins-Conti Products
  1359. Wavemaker 360
  1360. Waypoint Health Innovations
  1361. Wayra
  1362. WEA Trust
  1363. Webb Investment Network
  1364. Weill Cornell University
  1365. NYP Hospital
  1366. Vanderbilt University Medical Center
  1367. Welkin Health
  1368. WellBe
  1369. Welldoc
  1370. WellDyne
  1371. Wellington Management
  1372. Wellington Partners
  1373. Wells Fargo
  1374. Wellspan Health
  1375. Wellthy Therapeutics
  1376. Welltoc
  1377. Werth Family Investment Associates
  1378. Western Development Commission
  1379. White Fund
  1380. Wildflower Brands
  1381. Wildflower Health
  1382. Willis Towers Watson
  1383. Willow
  1384. Wings Fund
  1385. Wisconsin Investment Partners
  1386. Wisdom LLP
  1387. Wise Health System
  1388. Withings
  1389. Woebot Health
  1390. Wolfpack Digital
  1391. Women In Bio
  1392. Women in Data
  1393. WITI (Women in Technology International)
  1394. Women of Wearables (WoW)
  1395. Women's Health Connecticut  
  1396. WomenUP
  1397. Wonju Severance Christian Hospital
  1398. Woom
  1399. Workday Ventures
  1400. Workit Health
  1401. WP Global Partners
  1402. WPS Health Insurance
  1403. WRF Capital
  1404. Wrnch (Acquired by Hinge Health)
  1405. WVU Medicine
  1406. Xbird
  1407. Xpectives.Health
  1408. Y Combinator
  1409. Yesmom
  1410. Youturn Health
  1411. Yozma
  1412. Ysios Capital
  1413. Zaffre Investments
  1414. Zaya Care
  1415. Zendesk
  1416. ZENworks
  1417. Zero Mothers Die
  1418. Zillion
  1419. Zinc
  1420. Zoie Health
  1421. Zoll Medical
  1422. Zuellig Pharma
  1423. Zyus

Source 1: https://dtxalliance.org/understanding-dtx
Source 2: https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com